Organon & Co. (OGN) - Stock Analysis
Last updated: Jun 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative takeover/momentum catalyst: stock up about 125% over 21 trading days, driven by reports of Sun Pharma's binding $12B all-cash offer and possible final offer, plus VTAMA support from 2026 AAD pediatric atopic dermatitis guidelines.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong cash flow ⢠High leverage risk ⢠Thin equity OGN generates solid cash flow and adequate liquidity, but high leverage, thin equity, and limited interest coverage keep the investment case constrained despite steady margins.
Price Behavior
Key Price Behavior Insights: ⢠Tight range ⢠Building support ⢠Resistance cap Support Level: $13.34-$13.36 Resistance Level: $13.45-$13.46 OGN is consolidating in a tight $13.34-$13.46 range with RSI near 52, showing mild support around $13.34-$13.36 but resistance near $13.45-$13.46 until it breaks higher.
Sentiment & News
Key News Insights: ⢠Sale scrutiny ⢠FDA approvals ⢠Pipeline expansion OGN is drawing attention amid takeover-related scrutiny over the pending Sun Pharma sale, while FDA approvals, research presentations, and international partnerships support ongoing operational progress.
AI Summary
OGN has shifted from a standalone turnaround to a deal-arbitrage play, with Sun Pharma's $14.00 all-cash offer now anchoring valuation and capping upside, so the key investment takeaway is that returns hinge far more on clean transaction completion than on the company's weakening underlying operations. #M&Aâ
Description
Organon & Co. develops and commercializes prescription therapies globally, with a significant emphasis on women's health products, a portfolio of biosimilars in immunology and oncology, and established branded medicines across cardiovascular, respiratory, dermatology, bone health and pain management. The company distributes primarily to drug wholesalers and retailers, hospitals, government agencies and managed-care entities. Organon was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 27 | May 4 | OGN | Organon & Co. | Speculative takeover/momentum catalyst: stock up about 125% over 21 trading days, driven by reports of Sun Pharma's binding $12B all-cash offer and possible final offer, plus VTAMA support from 2026 AAD pediatric atopic dermatitis guidelines. | Closed | +0.8% |